Suvoda RTSM vs Veeva RTSM(RTSM / IRT)

Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.

Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.

Guide updated How we compare

Compare within RTSM / IRT

Study fit, side by side

These notes describe the products in the RTSM / IRT guide.

Suvoda RTSM

Best for
Oncology, CNS and rare disease sponsors who want IRT alongside eCOA, eConsent and patient payments on one platform
What to consider
Suvoda runs its RTSM on one platform with eCOA, eConsent and Greenphire patient payments, and offers pre-built API integrations with major EDCs. It publishes the shortest build claim on this list (kickoff to UAT in as little as two weeks, footnoted as preliminary testing) and an annual SOC 2 Type 2 audit for RTSM. Its public pages name stratification and adaptive designs but not minimization.
Read product profile

Veeva RTSM

Best for
Sponsors standardizing on the Veeva Clinical Platform who want RTSM connected to Veeva EDC, eCOA and CTMS
What to consider
Veeva RTSM lists a broad set of randomization schemas and productized connections to Veeva EDC, eCOA and CTMS, and a top-20 biopharma chose it as its enterprise standard in fiscal 2026. Public material does not describe direct-to-patient shipping or a dedicated forecasting tool, and no build timeline is published.
Read product profile

Compare the features

Both products use the same category definitions. Product order is editorial; products are not ranked.

Full RTSM / IRT feature comparison

Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.

Expand a feature definition or support note for context and its original source.

Suvoda RTSM vs Veeva RTSM (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category featureSuvoda RTSMVeeva RTSM
Randomization and blinding
Feature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Supported

Suvoda lists adaptive randomization, stratification, cohort and dose management and blinding management, but its public pages do not name minimization or dynamic allocation.

Source
About this support label

Adaptive and stratified randomization are stated; minimization or dynamic allocation is not named.

Extended support

Veeva lists static, stratified, dynamic/minimization, forced and adaptive schemas, re-randomization, capping and sentinel dosing.

Source
About this support label

Named methods explicitly include dynamic allocation and minimization.

Trial supply management
Feature definitions
Supported
Drug inventory, dispensing, shipping or resupply workflows are documented.
Extended support
Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Extended support

The RTSM page lists drug supply forecasting, direct-to-patient shipping, temperature excursion management, and accountability, returns and destruction.

Source
About this support label

Drug forecasting and direct-to-patient shipping are both named.

Supported

Veeva documents threshold, predictive and just-in-time resupply with expiry buffers and accountability, but no direct-to-patient shipping or separate forecasting tool.

Source
About this support label

Predictive resupply establishes base support; direct-to-patient shipping is not documented.

Study build speed and mid-study changes
Feature definitions
Supported
Study setup or post-go-live study changes are described.
Extended support
Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Supported

Suvoda states kickoff to UAT in as little as two weeks (footnoted as preliminary testing), and permissioned users can make common post-go-live changes without a change order.

Source
About this support label

The UAT timeline concerns preliminary testing; permissioned changes do not establish uninterrupted live use.

Supported

Authorized users can switch on cohorts and change limits mid-study, and Veeva says design-change amendments often take days rather than weeks; no initial build timeline is published.

Source
About this support label

Mid-study cohort and limit changes are stated; an initial build timeline and uninterrupted changes are not established.

Integrations and platform
Feature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Extended support

Suvoda reports integrations with more than 100 eClinical systems, standardized pre-built API integrations with top EDC providers and a REST API.

Source
About this support label

Pre-built EDC API integrations and a REST API are stated.

Supported

Productized connections send data to Veeva EDC, eCOA and DQS and take site data from Veeva CTMS, and the brief cites third-party EDC and shipping-provider connections.

Source
About this support label

Native and external trial-system connections establish base support; an API is not stated in this note.

Compliance and security evidence
Feature definitions
Supported
Relevant trial compliance or security controls are stated, with their scope identified.
Extended support
Relevant trial controls and a publicly accessible ISO certificate or SOC audit report covering the product or vendor are documented.
Supported

Suvoda says its RTSM adheres to 21 CFR Part 11 and that it maintains SOC 2 Type 2 compliance; its certifications page confirms an annual SOC 2 Type 2 audit for RTSM.

Source
About this support label

RTSM trial controls and an annual SOC audit are stated; public report access is not established.

Supported

Veeva's trust page lists ISO 27001 audits and a SOC 2 Type II report, but we found no RTSM-specific Part 11 or Annex 11 statement.

Source
About this support label

Vendor security audits are listed; RTSM-specific trial controls and public document access are not established.

Track record
Feature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Extended support

Suvoda reports 6,000+ trials and 115+ countries supported.

Source
About this support label

Product-specific trial adoption is reported across a stated country count.

Supported

Veeva reports that a top-20 biopharma selected Veeva RTSM as its enterprise standard (fiscal 2026); no total study or customer count for RTSM is published.

Source
About this support label

An enterprise-standard selection provides base track-record evidence; product-specific adoption figures are not published.

The guide update date reflects guide edits. Vendor statements are attributed in the evidence.

Keep the category in view

Compare these products with the other tools in the RTSM / IRT guide using the same feature definitions.

More RTSM / IRT comparisons featuring one of these products.